Innovent Reports First Patient Dosing in P-II Trial of IBI302 for Neovascular Age-Related Macular Degeneration

 Innovent Reports First Patient Dosing in P-II Trial of IBI302 for Neovascular Age-Related Macular Degeneration

Innovent Reports First Patient Dosing in P-II Trial of IBI302 for Neovascular Age-Related Macular Degeneration

Shots:

  • The first patient has been dosed in the P-II trial assessing IBI302 in patients with active subfoveal or parafoveal choroidal neovascularization secondary to nAMD. The primary objective is to evaluate the efficacy and safety of IBI302
  • The two P- I studies of IBI302 (single/multiple-dose escalation) showed improvement in visual acuity with a reduction in retinal thickness, leakage, and total area of neovascularization in terms of efficacy
  • Additionally, the ongoing P-II study of the therapy will focus on improving visual acuity and retinal thickness and the effect on macular atrophy and fibrosis

Click here to­ read full press release/ article | Ref: PRNewswire | Image: BioSpectrum Asia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post